Lyra Therapeutics (LYRA) News Today $0.18 +0.01 (+5.88%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial OutcomesNovember 15, 2024 | markets.businessinsider.comLyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 15, 2024 | finance.yahoo.comLyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comLyra Therapeutics, Inc. (LYRA)October 22, 2024 | finance.yahoo.comLyra Therapeutics completes Phase 3 trial enrollment for CRS treatmentOctober 17, 2024 | uk.investing.comLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisOctober 15, 2024 | globenewswire.comLyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsSeptember 27, 2024 | globenewswire.comLyra Therapeutics Insiders Still US$66k Away From Original Investment ValueAugust 22, 2024 | uk.finance.yahoo.comLyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comCeltic academy graduate Lawal makes permanent switch to StokeAugust 12, 2024 | bbc.comLyra Therapeutics, Inc. (LYRA) latest stock news & headlines – Yahoo FinanceJuly 19, 2024 | nz.finance.yahoo.comLyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?July 15, 2024 | insidermonkey.comMaintaining Hold on ProKidney: Balancing Market Potential Against Clinical UncertaintiesMay 29, 2024 | markets.businessinsider.comLyra to cut 75% of workforce in portfolio shakeupMay 21, 2024 | msn.comLyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalMay 21, 2024 | globenewswire.comTarget upgraded, CVS downgraded: Wall Street's top analyst callsMay 15, 2024 | finance.yahoo.comHold Rating on Lyra Therapeutics Amid Clinical Trial Setbacks and Financial UncertaintiesMay 7, 2024 | markets.businessinsider.comBTIG Downgrades Lyra Therapeutics (LYRA)May 7, 2024 | msn.comWhere Lyra Therapeutics Stands With AnalystsMay 7, 2024 | markets.businessinsider.comLyra Therapeutics (NASDAQ:LYRA) Cut to "Neutral" at HC WainwrightHC Wainwright downgraded shares of Lyra Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Tuesday.May 7, 2024 | marketbeat.comWhy Lyra Therapeutics Stock Is Down 93% TodayMay 6, 2024 | msn.comLyra Therapeutics's Phase 3 Enlighten Trial 1 Fails To Meet Primary Endpoint; Stock DownMay 6, 2024 | markets.businessinsider.comLyra Therapeutics Shares Plummet 90% After Chronic Rhinosinusitis Drug Fails in StudyMay 6, 2024 | marketwatch.comTrading was temporarily halted for "LYRA" at 12:05 PM with a stated reason of "LULD pause." Trading set to resume at 12:05 PM. May 6, 2024 | marketbeat.comWhy Is Lyra Therapeutics (LYRA) Stock Down 90% Today?May 6, 2024 | investorplace.comLyra Therapeutics Lead Drug Candidate Fails in Phase 3 StudyMay 6, 2024 | marketwatch.comLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisMay 6, 2024 | globenewswire.comTrading was temporarily halted for "LYRA" at 07:05 AM with a stated reason of "News pending."May 6, 2024 | marketbeat.comQ2 2024 EPS Estimates for Lyra Therapeutics, Inc. (NASDAQ:LYRA) Decreased by AnalystLyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) - Analysts at HC Wainwright reduced their Q2 2024 EPS estimates for Lyra Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earninMay 3, 2024 | marketbeat.comBuy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210May 2, 2024 | markets.businessinsider.comLyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 2, 2024 | finance.yahoo.comBuy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market PositioningMay 1, 2024 | markets.businessinsider.comBuy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market PotentialMay 1, 2024 | markets.businessinsider.comLyra Therapeutics' (LYRA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Lyra Therapeutics in a research report on Wednesday.May 1, 2024 | marketbeat.comLyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | globenewswire.comWorld's Best Digital Health Companies 2024 - TreatmentApril 26, 2024 | newsweek.comPrivate equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as wellMarch 26, 2024 | finance.yahoo.comLyra Therapeutics (NASDAQ:LYRA) Price Target Cut to $11.00Bank of America decreased their price target on shares of Lyra Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday.March 25, 2024 | marketbeat.comLyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS ProjectionsMarch 23, 2024 | finance.yahoo.comOptimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market OpportunityMarch 22, 2024 | markets.businessinsider.comLyra Therapeutics files for $300M mixed shelfMarch 22, 2024 | msn.comLyra Therapeutics (NASDAQ:LYRA) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Lyra Therapeutics in a research report on Friday.March 22, 2024 | marketbeat.comLyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Down 13.6% in FebruaryLyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 160,200 shares, a decline of 13.6% from the February 14th total of 185,400 shares. Based on an average daily trading volume, of 254,600 shares, the days-to-cover ratio is currently 0.6 days.March 16, 2024 | marketbeat.comLYRA Jul 2024 2.500 callMarch 15, 2024 | finance.yahoo.comLYRA Jul 2024 7.500 callMarch 15, 2024 | finance.yahoo.comLYRA Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comLYRA May 2024 7.500 callMarch 15, 2024 | finance.yahoo.comArmistice Capital LLC Cuts Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA)Armistice Capital LLC trimmed its position in Lyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) by 61.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,550,000 shares of the company's stock afterMarch 3, 2024 | marketbeat.com Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Combine the QQQ, IWM and SPY in one trade (Ad)If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses… You can find out about this “2-Click Trade” here. LYRA Media Mentions By Week LYRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYRA News Sentiment▼0.000.61▲Average Medical News Sentiment LYRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYRA Articles This Week▼01▲LYRA Articles Average Week Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ICAD News Today NTRB News Today LUCD News Today BLAC News Today CLGN News Today COCH News Today MDAI News Today SURG News Today XAIR News Today NXGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYRA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
